An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions
Abstract Early detection of atrial fibrillation (AF) enables initiation of anticoagulation and early rhythm control therapy to reduce stroke, cardiovascular death, and heart failure. In a cross-sectional, observational study, we aimed to identify a combination of circulating biomolecules reflecting...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-42331-7 |
| _version_ | 1827634559555993600 |
|---|---|
| author | Winnie Chua Victor R. Cardoso Eduard Guasch Moritz F. Sinner Christoph Al-Taie Paul Brady Barbara Casadei Harry J. G. M. Crijns Elton A. M. P. Dudink Stéphane N. Hatem Stefan Kääb Peter Kastner Lluis Mont Frantisek Nehaj Yanish Purmah Jasmeet S. Reyat Ulrich Schotten Laura C. Sommerfeld Stef Zeemering André Ziegler Georgios V. Gkoutos Paulus Kirchhof Larissa Fabritz |
| author_facet | Winnie Chua Victor R. Cardoso Eduard Guasch Moritz F. Sinner Christoph Al-Taie Paul Brady Barbara Casadei Harry J. G. M. Crijns Elton A. M. P. Dudink Stéphane N. Hatem Stefan Kääb Peter Kastner Lluis Mont Frantisek Nehaj Yanish Purmah Jasmeet S. Reyat Ulrich Schotten Laura C. Sommerfeld Stef Zeemering André Ziegler Georgios V. Gkoutos Paulus Kirchhof Larissa Fabritz |
| author_sort | Winnie Chua |
| collection | DOAJ |
| description | Abstract Early detection of atrial fibrillation (AF) enables initiation of anticoagulation and early rhythm control therapy to reduce stroke, cardiovascular death, and heart failure. In a cross-sectional, observational study, we aimed to identify a combination of circulating biomolecules reflecting different biological processes to detect prevalent AF in patients with cardiovascular conditions presenting to hospital. Twelve biomarkers identified by reviewing literature and patents were quantified on a high-precision, high-throughput platform in 1485 consecutive patients with cardiovascular conditions (median age 69 years [Q1, Q3 60, 78]; 60% male). Patients had either known AF (45%) or AF ruled out by 7-day ECG-monitoring. Logistic regression with backward elimination and a neural network approach considering 7 key clinical characteristics and 12 biomarker concentrations were applied to a randomly sampled discovery cohort (n = 933) and validated in the remaining patients (n = 552). In addition to age, sex, and body mass index (BMI), BMP10, ANGPT2, and FGF23 identified patients with prevalent AF (AUC 0.743 [95% CI 0.712, 0.775]). These circulating biomolecules represent distinct pathways associated with atrial cardiomyopathy and AF. Neural networks identified the same variables as the regression-based approach. The validation using regression yielded an AUC of 0.719 (95% CI 0.677, 0.762), corroborated using deep neural networks (AUC 0.784 [95% CI 0.745, 0.822]). Age, sex, BMI and three circulating biomolecules (BMP10, ANGPT2, FGF23) are associated with prevalent AF in unselected patients presenting to hospital. Findings should be externally validated. Results suggest that age and different disease processes approximated by these three biomolecules contribute to AF in patients. Our findings have the potential to improve screening programs for AF after external validation. |
| first_indexed | 2024-03-09T15:15:02Z |
| format | Article |
| id | doaj.art-d1c609a3c0d54b6f920d0755d796b56f |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-09T15:15:02Z |
| publishDate | 2023-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-d1c609a3c0d54b6f920d0755d796b56f2023-11-26T13:08:42ZengNature PortfolioScientific Reports2045-23222023-10-0113111210.1038/s41598-023-42331-7An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditionsWinnie Chua0Victor R. Cardoso1Eduard Guasch2Moritz F. Sinner3Christoph Al-Taie4Paul Brady5Barbara Casadei6Harry J. G. M. Crijns7Elton A. M. P. Dudink8Stéphane N. Hatem9Stefan Kääb10Peter Kastner11Lluis Mont12Frantisek Nehaj13Yanish Purmah14Jasmeet S. Reyat15Ulrich Schotten16Laura C. Sommerfeld17Stef Zeemering18André Ziegler19Georgios V. Gkoutos20Paulus Kirchhof21Larissa Fabritz22Institute of Cardiovascular Sciences, University of BirminghamInstitute of Cardiovascular Sciences, University of BirminghamHospital Clinic de Barcelona, Institute of Biomedical Research August Pi Sunyer (IDIBAPS)Department of Medicine I, University Hospital, LMUUniversity Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-EppendorfInstitute of Cardiovascular Sciences, University of BirminghamUniversity of OxfordCardiovascular Research Institute Maastricht (CARIM), Maastricht UniversityCardiovascular Research Institute Maastricht (CARIM), Maastricht UniversityIHU-ICAN Institute of Cardiometabolism and NutritionDepartment of Medicine I, University Hospital, LMURoche Diagnostics GmbHHospital Clinic de Barcelona, Institute of Biomedical Research August Pi Sunyer (IDIBAPS)Institute of Cardiovascular Sciences, University of BirminghamInstitute of Cardiovascular Sciences, University of BirminghamInstitute of Cardiovascular Sciences, University of BirminghamCardiovascular Research Institute Maastricht (CARIM), Maastricht UniversityInstitute of Cardiovascular Sciences, University of BirminghamCardiovascular Research Institute Maastricht (CARIM), Maastricht UniversityRoche Diagnostics International AGMRC Health Data Research UK (HDR)Institute of Cardiovascular Sciences, University of BirminghamInstitute of Cardiovascular Sciences, University of BirminghamAbstract Early detection of atrial fibrillation (AF) enables initiation of anticoagulation and early rhythm control therapy to reduce stroke, cardiovascular death, and heart failure. In a cross-sectional, observational study, we aimed to identify a combination of circulating biomolecules reflecting different biological processes to detect prevalent AF in patients with cardiovascular conditions presenting to hospital. Twelve biomarkers identified by reviewing literature and patents were quantified on a high-precision, high-throughput platform in 1485 consecutive patients with cardiovascular conditions (median age 69 years [Q1, Q3 60, 78]; 60% male). Patients had either known AF (45%) or AF ruled out by 7-day ECG-monitoring. Logistic regression with backward elimination and a neural network approach considering 7 key clinical characteristics and 12 biomarker concentrations were applied to a randomly sampled discovery cohort (n = 933) and validated in the remaining patients (n = 552). In addition to age, sex, and body mass index (BMI), BMP10, ANGPT2, and FGF23 identified patients with prevalent AF (AUC 0.743 [95% CI 0.712, 0.775]). These circulating biomolecules represent distinct pathways associated with atrial cardiomyopathy and AF. Neural networks identified the same variables as the regression-based approach. The validation using regression yielded an AUC of 0.719 (95% CI 0.677, 0.762), corroborated using deep neural networks (AUC 0.784 [95% CI 0.745, 0.822]). Age, sex, BMI and three circulating biomolecules (BMP10, ANGPT2, FGF23) are associated with prevalent AF in unselected patients presenting to hospital. Findings should be externally validated. Results suggest that age and different disease processes approximated by these three biomolecules contribute to AF in patients. Our findings have the potential to improve screening programs for AF after external validation.https://doi.org/10.1038/s41598-023-42331-7 |
| spellingShingle | Winnie Chua Victor R. Cardoso Eduard Guasch Moritz F. Sinner Christoph Al-Taie Paul Brady Barbara Casadei Harry J. G. M. Crijns Elton A. M. P. Dudink Stéphane N. Hatem Stefan Kääb Peter Kastner Lluis Mont Frantisek Nehaj Yanish Purmah Jasmeet S. Reyat Ulrich Schotten Laura C. Sommerfeld Stef Zeemering André Ziegler Georgios V. Gkoutos Paulus Kirchhof Larissa Fabritz An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions Scientific Reports |
| title | An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions |
| title_full | An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions |
| title_fullStr | An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions |
| title_full_unstemmed | An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions |
| title_short | An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions |
| title_sort | angiopoietin 2 fgf23 and bmp10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions |
| url | https://doi.org/10.1038/s41598-023-42331-7 |
| work_keys_str_mv | AT winniechua anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT victorrcardoso anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT eduardguasch anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT moritzfsinner anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT christophaltaie anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT paulbrady anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT barbaracasadei anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT harryjgmcrijns anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT eltonampdudink anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT stephanenhatem anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT stefankaab anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT peterkastner anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT lluismont anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT frantiseknehaj anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT yanishpurmah anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT jasmeetsreyat anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT ulrichschotten anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT lauracsommerfeld anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT stefzeemering anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT andreziegler anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT georgiosvgkoutos anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT pauluskirchhof anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT larissafabritz anangiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT winniechua angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT victorrcardoso angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT eduardguasch angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT moritzfsinner angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT christophaltaie angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT paulbrady angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT barbaracasadei angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT harryjgmcrijns angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT eltonampdudink angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT stephanenhatem angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT stefankaab angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT peterkastner angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT lluismont angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT frantiseknehaj angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT yanishpurmah angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT jasmeetsreyat angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT ulrichschotten angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT lauracsommerfeld angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT stefzeemering angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT andreziegler angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT georgiosvgkoutos angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT pauluskirchhof angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions AT larissafabritz angiopoietin2fgf23andbmp10biomarkersignaturedifferentiatesatrialfibrillationfromotherconcomitantcardiovascularconditions |